|
|
|
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME |
|
|
(Unaudited) |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended December 31, |
|
|
Six Months Ended December 31, |
|
| |
|
2011 |
|
|
2010 |
|
|
2011 |
|
|
2010 |
|
|
REVENUE |
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical products |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
26,673 |
|
|
Services |
|
|
2,659,182 |
|
|
|
553,038 |
|
|
|
5,223,765 |
|
|
|
553,038 |
|
| |
|
|
2,659,182 |
|
|
|
553,038 |
|
|
|
5,223,765 |
|
|
|
579,711 |
|
|
COST OF SALES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical products |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
24,299 |
|
|
Services |
|
|
441,349 |
|
|
|
68,872 |
|
|
|
675,181 |
|
|
|
68,872 |
|
|
Business and sales related tax |
|
|
148,830 |
|
|
|
- |
|
|
|
278,142 |
|
|
|
- |
|
| |
|
|
590,179 |
|
|
|
68,872 |
|
|
|
953,323 |
|
|
|
93,171 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GROSS PROFIT |
|
|
2,069,003 |
|
|
|
484,166 |
|
|
|
4,270,442 |
|
|
|
486,540 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COSTS AND EXPENSES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and Administrative Expenses |
|
|
72,514 |
|
|
|
64,858 |
|
|
|
187,153 |
|
|
|
98,737 |
|
|
OPERATING INCOME |
|
|
1,996,489 |
|
|
|
419,308 |
|
|
|
4,083,289 |
|
|
|
387,803 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER INCOME |
|
|
6,348 |
|
|
|
- |
|
|
|
7,402 |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INCOME BEFORE INCOME TAX |
|
|
2,002,837 |
|
|
|
419,308 |
|
|
|
4,090,691 |
|
|
|
387,803 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INCOME TAX |
|
|
397,729 |
|
|
|
106,993 |
|
|
|
873,295 |
|
|
|
100,060 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET INCOME |
|
|
1,605,108 |
|
|
|
312,315 |
|
|
|
3,217,396 |
|
|
|
287,743 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LESS: NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS |
|
|
74,695 |
|
|
|
15,995 |
|
|
|
157,371 |
|
|
|
14,437 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET INCOME ATTRIBUTABLE TO THE COMPANY |
|
|
1,530,413 |
|
|
|
296,320 |
|
|
|
3,060,025 |
|
|
|
273,306 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER COMPREHENSIVE INCOME |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation gain, net of tax |
|
|
56,457 |
|
|
|
20,011 |
|
|
|
128,076 |
|
|
|
39,938 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COMPREHENSIVE INCOME |
|
|
1,586,870 |
|
|
|
316,331 |
|
|
|
3,188,101 |
|
|
|
313,244 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LESS: OTHER COMPREHENSIVE INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS |
|
|
2,823 |
|
|
|
10,512 |
|
|
|
7,516 |
|
|
|
26,581 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COMPREHENSIVE INCOME ATTRIBUTABLE TO THE COMPANY |
|
$ |
1,584,047 |
|
|
$ |
305,819 |
|
|
$ |
3,180,585 |
|
|
$ |
286,663 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted earnings per common share |
|
$ |
0.04 |
|
|
$ |
0.01 |
|
|
$ |
0.08 |
|
|
$ |
0.01 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding |
|
|
40,665,063 |
|
|
|
40,665,063 |
|
|
|
40,665,063 |
|
|
|
40,665,063 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated financial statements. |
|
Advanced Description :
No additional details have been entered yet. If you would like to moderate the board and provide an advanced description for this stock, please send a Board Moderation Request at top left of board.